Charité – Universitätsmedizin Berlin, Germany, has published a press release about the new treatment concepts for PJI.
Here his feedback:
Implant-associated infections continue to represent a challenge to modern medicine, mainly due to insufficient antibiotic concentration at the site of infection. With this innovative project we are developing a new strategy that combines the power of local delivery ("click chemistry") and the flexibility of systemic delivery without systemic toxicity.
Streptococci account for 10-20% of orthopedic implant-associated infections, including prosthetic joints, spine, native joints and breast implants. Moreover, streptococci are the most common organisms causing intravascular infections, both of native valves (infective endocarditis), as well as device-associated such as cardiac pacemaker/ICD, vascular prosthesis or prosthetic valve endocarditis.
Biofilm microorganisms are up to 1,000 times more resistant to antibiotics than their planktonic (free-living) counterparts. The increasing development of antibiotic resistance problems lead to the investigation of new ways to fight biofilm infections, such as the use of bacteriophages.
Here his feedback:
Here her feedback:
On October 20-23, 2015 the DKOU - Congress of Orthopedics and Traumatology will take place in Berlin, Germany.
During this congress the wide range of knowledge and know-how in orthopedics and trauma surgery will be shared with the colleagues from all over the world. For the first time it has been calling for abstracts in English and building up international sessions in English.
On November 18, 2015 the Consilium Infectiorum Workshop on implants and biofilms will take place in Essen, Germany. The aim of this workshop is to look at the biofilm from different angles to optimize the therapy and prevent persistence and recurrence of infection.